Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis
Recruiting now
Conditions studied: Chronic Rhinosinusitis With Nasal Polyps
In brief
The central hypothesis of this study is that the addition of dupilumab treatment onto standard-of-care intranasal corticosteroids will improve patient-reported measures of disease activity and sense of smell in a cohort of mostly ethnical and racial minority patients with CRSwNP
Key facts
- Study ID
- NCT05246267
- Run by
- Montefiore Medical Center
- People needed
- 60
- Starts
- 2022-02-15
- Expected to finish
- 2026-06-01
- Last updated by the study team
- 2026-01-22
Who can join
Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with physician-diagnosed CRSwNP, with or without comorbid asthma that meet indication criteria for FDA-approved use of Dupilumab.
- Patients aged 18 years and older.
- Patient willing to provide consent to be a participant in the study.
- Patients with insurance that allows Dupilumab coverage or Dupilumab coverage obtained through "Dupixent MyWay Program"
You may not qualify if…
- Age under 18
- Suspected or diagnosed allergic fungal rhinosinusitis.
- Suspected or diagnosed cystic fibrosis.
- Dupilumab coverage denied through insurance or "Dupixent MyWay Program"
- Patients who required a steroid taper in the preceding 30 days. However, patients on chronic steroids less or equal to 20 mg of prednisone daily, are eligible.
- Patients who were on a different biologic medication in the preceding 3 months.
- Patients with a diagnosis of EGPA/Churg-Strauss Syndrome
- Pregnant patients
- Patients with inverted papilloma growth
Where it is running
- Montefiore Medical Center — The Bronx, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.